Laboratorio di Chimica Bioorganica, Dipartimento di Fisica, Università di Trento, Via Sommarive 14, 38123 Trento, Italy.
Int J Mol Sci. 2022 Jan 4;23(1):518. doi: 10.3390/ijms23010518.
(1,5)-1-Hydroxy-3,6-dioxa-bicyclo[3.2.1]octan-2-one, available by an efficient catalytic pyrolysis of cellulose, has been applied as a chiral building block in the synthesis of seven new nucleoside analogues, with structural modifications on the nucleobase moiety and on the carboxyl- derived unit. The inverted configuration by Mitsunobu reaction used in their synthesis was verified by 2D-NOESY correlations, supported by the optimized structure employing the DFT methods. An in silico screening of these compounds as inhibitors of SARS-CoV-2 RNA-dependent RNA polymerase has been carried out in comparison with both remdesivir, a mono-phosphoramidate prodrug recently approved for COVID-19 treatment, and its ribonucleoside metabolite GS-441524. Drug-likeness prediction and data by docking calculation indicated compound [=(3,5)-methyl 5-(hydroxymethyl)-3-(6-(4-methylpiperazin-1-yl)-9H-purin-9-yl)tetrahydrofuran-3-carboxylate] as the best candidate. Furthermore, molecular dynamics simulation showed a stable interaction of structure in RNA-dependent RNA polymerase (RdRp) complex and a lower average atomic fluctuation than GS-441524, suggesting a well accommodation in the RdRp binding pocket.
(1,5)-1-羟基-3,6-二氧杂双环[3.2.1]辛烷-2-酮可通过纤维素的高效催化热解获得,已被用作合成七个新核苷类似物的手性构建块,对碱基部分和羧基衍生单元进行了结构修饰。通过二维 NOESY 相关实验证实了它们合成中使用的 Mitsunobu 反应的反式构型,该实验得到了使用 DFT 方法优化的结构的支持。对这些化合物作为 SARS-CoV-2 RNA 依赖性 RNA 聚合酶抑制剂的进行了计算机筛选,与最近被批准用于 COVID-19 治疗的单磷酰胺前药瑞德西韦和其核糖核苷代谢物 GS-441524 进行了比较。药物相似性预测和对接计算数据表明,化合物[=(3,5)-甲基 5-(羟甲基)-3-(6-(4-甲基哌嗪-1-基)-9H-嘌呤-9-基)四氢呋喃-3-羧酸酯]为最佳候选物。此外,分子动力学模拟表明结构在 RNA 依赖性 RNA 聚合酶(RdRp)复合物中的稳定相互作用和比 GS-441524 更低的平均原子波动,表明其在 RdRp 结合口袋中有良好的适应性。